Global Antihypertensive Sales Market Report 2021

1 Antihypertensive Market Overview

• 1.1 Antihypertensive Product Scope
• 1.2 Antihypertensive Segment by Type
  • 1.2.1 Global Antihypertensive Sales by Type (2016 & 2021 & 2027)
  • 1.2.2 Diuretics
  • 1.2.3 Angiotensin Converting Enzyme (ACE) Inhibitors
  • 1.2.4 Angiotensin Receptor Blockers (ARBs)
  • 1.2.5 Calcium Channel Blockers
  • 1.2.6 Beta Blockers
  • 1.2.7 Alpha Blockers
  • 1.2.8 Vasodilators & Renin Inhibitors
• 1.3 Antihypertensive Segment by Application
  • 1.3.1 Global Antihypertensive Sales Comparison by Application (2016 & 2021 & 2027)
  • 1.3.2 Hospital Pharmacy
  • 1.3.3 Retail Pharmacy
  • 1.3.4 Online Pharmacy
  • 1.3.5 Others
• 1.4 Antihypertensive Market Estimates and Forecasts (2016-2027)
  • 1.4.1 Global Antihypertensive Market Size in Value Growth Rate (2016-2027)
  • 1.4.2 Global Antihypertensive Market Size in Volume Growth Rate (2016-2027)
  • 1.4.3 Global Antihypertensive Price Trends (2016-2027)

2 Antihypertensive Estimates and Forecasts by Region

• 2.1 Global Antihypertensive Market Size by Region: 2016 VS 2021 VS 2027
• 2.2 Global Antihypertensive Retrospective Market Scenario by Region (2016-2021)
  • 2.2.1 Global Antihypertensive Sales Market Share by Region (2016-2021)
  • 2.2.2 Global Antihypertensive Revenue Market Share by Region (2016-2021)
• 2.3 Global Antihypertensive Market Estimates and Forecasts by Region (2022-2027)
  • 2.3.1 Global Antihypertensive Sales Estimates and Forecasts by Region (2022-2027)
  • 2.3.2 Global Antihypertensive Revenue Forecast by Region (2022-2027)
• 2.4 Geographic Market Analysis: Market Facts & Figures
  • 2.4.1 North America Antihypertensive Estimates and Projections (2016-2027)
  • 2.4.2 Europe Antihypertensive Estimates and Projections (2016-2027)
  • 2.4.3 China Antihypertensive Estimates and Projections (2016-2027)
  • 2.4.4 Japan Antihypertensive Estimates and Projections (2016-2027)
  • 2.4.5 Southeast Asia Antihypertensive Estimates and Projections (2016-2027)
  • 2.4.6 India Antihypertensive Estimates and Projections (2016-2027)

3 Global Antihypertensive Competition Landscape by Players

• 3.1 Global Top Antihypertensive Players by Sales (2016-2021)
• 3.2 Global Top Antihypertensive Players by Revenue (2016-2021)
• 3.3 Global Antihypertensive Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Antihypertensive as of 2020)
• 3.4 Global Antihypertensive Average Price by Company (2016-2021)
• 3.5 Manufacturers Antihypertensive Manufacturing Sites, Area Served, Product Type
• 3.6 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Global Antihypertensive Market Size by Type

• 4.1 Global Antihypertensive Historic Market Review by Type (2016-2021)
  • 4.1.1 Global Antihypertensive Sales Market Share by Type (2016-2021)
  • 4.1.2 Global Antihypertensive Revenue Market Share by Type (2016-2021)
  • 4.1.3 Global Antihypertensive Price by Type (2016-2021)
• 4.2 Global Antihypertensive Market Estimates and Forecasts by Type (2022-2027)
  • 4.2.1 Global Antihypertensive Sales Forecast by Type (2022-2027)
  • 4.2.2 Global Antihypertensive Revenue Forecast by Type (2022-2027)
  • 4.2.3 Global Antihypertensive Price Forecast by Type (2022-2027)

5 Global Antihypertensive Market Size by Application

• 5.1 Global Antihypertensive Historic Market Review by Application (2016-2021)
  • 5.1.1 Global Antihypertensive Sales Market Share by Application (2016-2021)
  • 5.1.2 Global Antihypertensive Revenue Market Share by Application (2016-2021)
  • 5.1.3 Global Antihypertensive Price by Application (2016-2021)
• 5.2 Global Antihypertensive Market Estimates and Forecasts by Application (2022-2027)
  • 5.2.1 Global Antihypertensive Sales Forecast by Application (2022-2027)
  • 5.2.2 Global Antihypertensive Revenue Forecast by Application (2022-2027)
  • 5.2.3 Global Antihypertensive Price Forecast by Application (2022-2027)

6 North America Antihypertensive Market Facts & Figures

• 6.1 North America Antihypertensive Sales by Company
  • 6.1.1 North America Antihypertensive Sales by Company (2016-2021)
  • 6.1.2 North America Antihypertensive Revenue by Company (2016-2021)
• 6.2 North America Antihypertensive Sales Breakdown by Type
  • 6.2.1 North America Antihypertensive Sales Breakdown by Type (2016-2021)
  • 6.2.2 North America Antihypertensive Sales Breakdown by Type (2022-2027)
• 6.3 North America Antihypertensive Sales Breakdown by Application
  • 6.3.1 North America Antihypertensive Sales Breakdown by Application (2016-2021)
  • 6.3.2 North America Antihypertensive Sales Breakdown by Application (2022-2027)

7 Europe Antihypertensive Market Facts & Figures

• 7.1 Europe Antihypertensive Sales by Company
  • 7.1.1 Europe Antihypertensive Sales by Company (2016-2021)
  • 7.1.2 Europe Antihypertensive Revenue by Company (2016-2021)
• 7.2 Europe Antihypertensive Sales Breakdown by Type
  • 7.2.1 Europe Antihypertensive Sales Breakdown by Type (2016-2021)
  • 7.2.2 Europe Antihypertensive Sales Breakdown by Type (2022-2027)
• 7.3 Europe Antihypertensive Sales Breakdown by Application
  • 7.3.1 Europe 147 Sales Breakdown by Application (2016-2021)
  • 7.3.2 Europe 147 Sales Breakdown by Application (2022-2027)

8 China Antihypertensive Market Facts & Figures

• 8.1 China Antihypertensive Sales by Company
  • 8.1.1 China Antihypertensive Sales by Company (2016-2021)
  • 8.1.2 China Antihypertensive Revenue by Company (2016-2021)
• 8.2 China Antihypertensive Sales Breakdown by Type
  • 8.2.1 China Antihypertensive Sales Breakdown by Type (2016-2021)
  • 8.2.2 China Antihypertensive Sales Breakdown by Type (2022-2027)
• 8.3 China Antihypertensive Sales Breakdown by Application
  • 8.3.1 China 178 Sales Breakdown by Application (2016-2021)
  • 8.3.2 China 178 Sales Breakdown by Application (2022-2027)

9 Japan Antihypertensive Market Facts & Figures

• 9.1 Japan Antihypertensive Sales by Company
  • 9.1.1 Japan Antihypertensive Sales by Company (2016-2021)
  • 9.1.2 Japan Antihypertensive Revenue by Company (2016-2021)
• 9.2 Japan Antihypertensive Sales Breakdown by Type
  • 9.2.1 Japan Antihypertensive Sales Breakdown by Type (2016-2021)
  • 9.2.2 Japan Antihypertensive Sales Breakdown by Type (2022-2027)
• 9.3 Japan Antihypertensive Sales Breakdown by Application
  • 9.3.1 Japan Feb. Sales Breakdown by Application (2016-2021)
  • 9.3.2 Japan Feb. Sales Breakdown by Application (2022-2027)

10 Southeast Asia Antihypertensive Market Facts & Figures

• 10.1 Southeast Asia Antihypertensive Sales by Company
  • 10.1.1 Southeast Asia Antihypertensive Sales by Company (2016-2021)
  • 10.1.2 Southeast Asia Antihypertensive Revenue by Company (2016-2021)
• 10.2 Southeast Asia Antihypertensive Sales Breakdown by Type
  • 10.2.1 Southeast Asia Antihypertensive Sales Breakdown by Type (2016-2021)
  • 10.2.2 Southeast Asia Antihypertensive Sales Breakdown by Type (2022-2027)
• 10.3 Southeast Asia Antihypertensive Sales Breakdown by Application
  • 10.3.1 Southeast Asia K Units Sales Breakdown by Application (2016-2021)
  • 10.3.2 Southeast Asia K Units Sales Breakdown by Application (2022-2027)

11 India Antihypertensive Market Facts & Figures

• 11.1 India Antihypertensive Sales by Company
  • 11.1.1 India Antihypertensive Sales by Company (2016-2021)
  • 11.1.2 India Antihypertensive Revenue by Company (2016-2021)
• 11.2 India Antihypertensive Sales Breakdown by Type
  • 11.2.1 India Antihypertensive Sales Breakdown by Type (2016-2021)
  • 11.2.2 India Antihypertensive Sales Breakdown by Type (2022-2027)
• 11.3 India Antihypertensive Sales Breakdown by Application
  • 11.3.1 India Antihypertensive Sales Breakdown by Application (2016-2021)
  • 11.3.2 India Antihypertensive Sales Breakdown by Application (2022-2027)

12 Company Profiles and Key Figures in Antihypertensive Business

• 12.1 Pfizer
  • 12.1.1 Pfizer Corporation Information
  • 12.1.2 Pfizer Business Overview
  • 12.1.3 Pfizer Antihypertensive Sales, Revenue and Gross Margin (2016-2021)
  • 12.1.4 Pfizer Antihypertensive Products Offered
  • 12.1.5 Pfizer Recent Development
• 12.2 Norvatis
  • 12.2.1 Norvatis Corporation Information
  • 12.2.2 Norvatis Business Overview
  • 12.2.3 Norvatis Antihypertensive Sales, Revenue and Gross Margin (2016-2021)
  • 12.2.4 Norvatis Antihypertensive Products Offered
  • 12.2.5 Norvatis Recent Development
• 12.3 Merck & Co.
  • 12.3.1 Merck & Co. Corporation Information
  • 12.3.2 Merck & Co. Business Overview
  • 12.3.3 Merck & Co. Antihypertensive Sales, Revenue and Gross Margin (2016-2021)
  • 12.3.4 Merck & Co. Antihypertensive Products Offered
  • 12.3.5 Merck & Co. Recent Development
• 12.4 Sanofi
  • 12.4.1 Sanofi Corporation Information
  • 12.4.2 Sanofi Business Overview
  • 12.4.3 Sanofi Antihypertensive Sales, Revenue and Gross Margin (2016-2021)
  • 12.4.4 Sanofi Antihypertensive Products Offered
  • 12.4.5 Sanofi Recent Development
• 12.5 AstraZeneca
  • 12.5.1 AstraZeneca Corporation Information
  • 12.5.2 AstraZeneca Business Overview
  • 12.5.3 AstraZeneca Antihypertensive Sales, Revenue and Gross Margin (2016-2021)
  • 12.5.4 AstraZeneca Antihypertensive Products Offered
  • 12.5.5 AstraZeneca Recent Development
• 12.6 GSK
  • 12.6.1 GSK Corporation Information
  • 12.6.2 GSK Business Overview
  • 12.6.3 GSK Antihypertensive Sales, Revenue and Gross Margin (2016-2021)
  • 12.6.4 GSK Antihypertensive Products Offered
  • 12.6.5 GSK Recent Development
• 12.7 Daiichi-Sankyo
  • 12.7.1 Daiichi-Sankyo Corporation Information
  • 12.7.2 Daiichi-Sankyo Business Overview
  • 12.7.3 Daiichi-Sankyo Antihypertensive Sales, Revenue and Gross Margin (2016-2021)
  • 12.7.4 Daiichi-Sankyo Antihypertensive Products Offered
  • 12.7.5 Daiichi-Sankyo Recent Development
• 12.8 Boehringer-Ingelheim
  • 12.8.1 Boehringer-Ingelheim Corporation Information
  • 12.8.2 Boehringer-Ingelheim Business Overview
  • 12.8.3 Boehringer-Ingelheim Antihypertensive Sales, Revenue and Gross Margin (2016-2021)
  • 12.8.4 Boehringer-Ingelheim Antihypertensive Products Offered
  • 12.8.5 Boehringer-Ingelheim Recent Development
• 12.9 Bayer
  • 12.9.1 Bayer Corporation Information
  • 12.9.2 Bayer Business Overview
  • 12.9.3 Bayer Antihypertensive Sales, Revenue and Gross Margin (2016-2021)
  • 12.9.4 Bayer Antihypertensive Products Offered
  • 12.9.5 Bayer Recent Development
• 12.10 Johnson & Johnson
  • 12.10.1 Johnson & Johnson Corporation Information
  • 12.10.2 Johnson & Johnson Business Overview
  • 12.10.3 Johnson & Johnson Antihypertensive Sales, Revenue and Gross Margin (2016-2021)
  • 12.10.4 Johnson & Johnson Antihypertensive Products Offered
  • 12.10.5 Johnson & Johnson Recent Development
• 12.11 Bristol-Myers Squibb
  • 12.11.1 Bristol-Myers Squibb Corporation Information
  • 12.11.2 Bristol-Myers Squibb Business Overview
  • 12.11.3 Bristol-Myers Squibb Antihypertensive Sales, Revenue and Gross Margin (2016-2021)
  • 12.11.4 Bristol-Myers Squibb Antihypertensive Products Offered
  • 12.11.5 Bristol-Myers Squibb Recent Development
• 12.12 Tekeda
  • 12.12.1 Tekeda Corporation Information
  • 12.12.2 Tekeda Business Overview
  • 12.12.3 Tekeda Antihypertensive Sales, Revenue and Gross Margin (2016-2021)
  • 12.12.4 Tekeda Antihypertensive Products Offered
  • 12.12.5 Tekeda Recent Development
• 12.13 Ranbaxy Laboratories
  • 12.13.1 Ranbaxy Laboratories Corporation Information
  • 12.13.2 Ranbaxy Laboratories Business Overview
  • 12.13.3 Ranbaxy Laboratories Antihypertensive Sales, Revenue and Gross Margin (2016-2021)
  • 12.13.4 Ranbaxy Laboratories Antihypertensive Products Offered
  • 12.13.5 Ranbaxy Laboratories Recent Development
• 12.14 Shihuida Pharm
  • 12.14.1 Shihuida Pharm Corporation Information
  • 12.14.2 Shihuida Pharm Business Overview
  • 12.14.3 Shihuida Pharm Antihypertensive Sales, Revenue and Gross Margin (2016-2021)
  • 12.14.4 Shihuida Pharm Antihypertensive Products Offered
  • 12.14.5 Shihuida Pharm Recent Development
• 12.15 Second Pharmaceutical
  • 12.15.1 Second Pharmaceutical Corporation Information
  • 12.15.2 Second Pharmaceutical Business Overview
  • 12.15.3 Second Pharmaceutical Antihypertensive Sales, Revenue and Gross Margin (2016-2021)
  • 12.15.4 Second Pharmaceutical Antihypertensive Products Offered
  • 12.15.5 Second Pharmaceutical Recent Development
• 12.16 Lupin Limited.
  • 12.16.1 Lupin Limited. Corporation Information
  • 12.16.2 Lupin Limited. Business Overview
  • 12.16.3 Lupin Limited. Antihypertensive Sales, Revenue and Gross Margin (2016-2021)
  • 12.16.4 Lupin Limited. Antihypertensive Products Offered
  • 12.16.5 Lupin Limited. Recent Development
• 12.17 Yangtze River Pharmaceutical
  • 12.17.1 Yangtze River Pharmaceutical Corporation Information
  • 12.17.2 Yangtze River Pharmaceutical Business Overview
  • 12.17.3 Yangtze River Pharmaceutical Antihypertensive Sales, Revenue and Gross Margin (2016-2021)
  • 12.17.4 Yangtze River Pharmaceutical Antihypertensive Products Offered
  • 12.17.5 Yangtze River Pharmaceutical Recent Development
• 12.18 Hengrui Medicine
  • 12.18.1 Hengrui Medicine Corporation Information
  • 12.18.2 Hengrui Medicine Business Overview
  • 12.18.3 Hengrui Medicine Antihypertensive Sales, Revenue and Gross Margin (2016-2021)
  • 12.18.4 Hengrui Medicine Antihypertensive Products Offered
  • 12.18.5 Hengrui Medicine Recent Development
• 12.19 Qilu Pharmaceutical
  • 12.19.1 Qilu Pharmaceutical Corporation Information
  • 12.19.2 Qilu Pharmaceutical Business Overview
  • 12.19.3 Qilu Pharmaceutical Antihypertensive Sales, Revenue and Gross Margin (2016-2021)
  • 12.19.4 Qilu Pharmaceutical Antihypertensive Products Offered
  • 12.19.5 Qilu Pharmaceutical Recent Development
• 12.20 HUALON
  • 12.20.1 HUALON Corporation Information
  • 12.20.2 HUALON Business Overview
  • 12.20.3 HUALON Antihypertensive Sales, Revenue and Gross Margin (2016-2021)
  • 12.20.4 HUALON Antihypertensive Products Offered
  • 12.20.5 HUALON Recent Development
• 12.21 Dawnrays
  • 12.21.1 Dawnrays Corporation Information
  • 12.21.2 Dawnrays Business Overview
  • 12.21.3 Dawnrays Antihypertensive Sales, Revenue and Gross Margin (2016-2021)
  • 12.21.4 Dawnrays Antihypertensive Products Offered
  • 12.21.5 Dawnrays Recent Development
• 12.22 HISUN Pharmceutical
  • 12.22.1 HISUN Pharmceutical Corporation Information
  • 12.22.2 HISUN Pharmceutical Business Overview
  • 12.22.3 HISUN Pharmceutical Antihypertensive Sales, Revenue and Gross Margin (2016-2021)
  • 12.22.4 HISUN Pharmceutical Antihypertensive Products Offered
  • 12.22.5 HISUN Pharmceutical Recent Development

13 Antihypertensive Manufacturing Cost Analysis

• 13.1 Antihypertensive Key Raw Materials Analysis
  • 13.1.1 Key Raw Materials
  • 13.1.2 Key Raw Materials Price Trend
  • 13.1.3 Key Suppliers of Raw Materials
• 13.2 Proportion of Manufacturing Cost Structure
• 13.3 Manufacturing Process Analysis of Antihypertensive
• 13.4 Antihypertensive Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers

• 14.1 Marketing Channel
• 14.2 Antihypertensive Distributors List
• 14.3 Antihypertensive Customers

15 Market Dynamics

• 15.1 Antihypertensive Market Trends
• 15.2 Antihypertensive Drivers
• 15.3 Antihypertensive Market Challenges
• 15.4 Antihypertensive Market Restraints

16 Research Findings and Conclusion

17 Appendix

• 17.1 Research Methodology
  • 17.1.1 Methodology/Research Approach
  • 17.1.2 Data Source
• 17.2 Author List